Published in Vaccine Weekly, November 29th, 1999
Currently, adults with chronic liver disease, users of injectable drugs (UID), men who have sex with men, and travelers to endemic areas are recommended to undergo hepatitis A virus (HAV) vaccination due to increased risk of HAV infection and/or morbidity. However, it is unclear if anti-HAV serology should be determined prior to vaccination.
In this study, Sammy Saab and colleagues from the University of California at Los Angeles compared the costs of two HAV vaccination strategies for high risk populations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.